Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$3.47 +1.2%	$3.77	$3.04 ▼ $8.44	$189.84M	1.17	187,302 shs	93,276 shs
ESPR Esperion Therapeutics	$0.91 -1.4%	$1.38	$0.82 ▼ $3.94	$179.78M	0.86	5.63 million shs	2.94 million shs
FSDDF FSD Pharma	$7.08 +2.5%	$6.12	$3.43 ▼ $68.66	$53.67M	N/A	11,100 shs	49,879 shs
OCGN Ocugen	$0.71 -1.3%	$0.64	$0.52 ▼ $2.06	$193.31M	3.78	4.68 million shs	3.32 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	+1.17%	+1.76%	+2.36%	-39.55%	-37.14%
ESPR Esperion Therapeutics	-1.38%	+6.49%	-39.51%	-53.47%	-52.25%
FSDDF FSD Pharma	0.00%	+12.38%	-17.29%	+143.30%	+1,375.31%
OCGN Ocugen	-1.28%	+4.86%	-11.19%	-0.28%	-44.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTMD biote	3.834 of 5 stars	3.5	5.0	0.0	0.0	2.9	3.3	1.3
ESPR Esperion Therapeutics	3.3748 of 5 stars	3.3	1.0	0.0	3.9	1.8	1.7	0.6
FSDDF FSD Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	1.0924 of 5 stars	3.5	0.0	0.0	0.0	2.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	3.00	Buy	$8.00	130.55% Upside
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.42	607.23% Upside
FSDDF FSD Pharma	0.00	N/A	N/A	N/A
OCGN Ocugen	3.00	Buy	$6.33	792.02% Upside

Current Analyst Ratings Breakdown

Latest FSDDF, ESPR, OCGN, and BTMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/20/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/13/2025	BTMD biote	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
3/6/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/6/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/4/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
2/13/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
2/13/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$197.19M	0.96	$0.36 per share	9.60	($0.58) per share	-5.98
ESPR Esperion Therapeutics	$332.31M	0.54	N/A	N/A	($3.85) per share	-0.24
FSDDF FSD Pharma	$70K	766.66	N/A	N/A	N/A	∞
OCGN Ocugen	$4.06M	51.13	N/A	N/A	$0.16 per share	4.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$3.32M	$0.18	13.35	6.43	N/A	5.20%	-32.41%	22.26%	5/7/2025 (Estimated)
ESPR Esperion Therapeutics	-$209.25M	-$0.25	N/A	N/A	N/A	-29.37%	N/A	-10.77%	5/6/2025 (Estimated)
FSDDF FSD Pharma	-$17.52M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	-$63.08M	-$0.19	N/A	N/A	N/A	-532.51%	-154.75%	-90.79%	5/13/2025 (Estimated)

Latest FSDDF, ESPR, OCGN, and BTMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OCGN Ocugen	-$0.06	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	BTMD biote	$0.06	N/A	N/A	N/A	$47.25 million	N/A
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	N/A	N/A	N/A	$54.97 million	N/A
3/5/2025	Q4 2024	OCGN Ocugen	-$0.05	-$0.05	N/A	-$0.05	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
FSDDF FSD Pharma	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	1.50	1.16
ESPR Esperion Therapeutics	N/A	1.85	1.37
FSDDF FSD Pharma	N/A	1.81	1.60
OCGN Ocugen	0.04	2.58	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
ESPR Esperion Therapeutics	47.39%
FSDDF FSD Pharma	0.43%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
BTMD biote	24.00%
ESPR Esperion Therapeutics	1.00%
FSDDF FSD Pharma	N/A
OCGN Ocugen	4.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	54.71 million	46.78 million	Not Optionable
ESPR Esperion Therapeutics	200	198.15 million	195.07 million	Optionable
FSDDF FSD Pharma	10	7.58 million	N/A	Not Optionable
OCGN Ocugen	80	292.01 million	278.82 million	Optionable

FSDDF, ESPR, OCGN, and BTMD Headlines

Recent News About These Companies

Renaissance Technologies LLC Invests $1.68 Million in Ocugen, Inc. (NASDAQ:OCGN)

April 29 at 3:42 AM | marketbeat.com

Ocugen Inc. stock rises Tuesday, still underperforms market

April 23, 2025 | marketwatch.com

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?

April 17, 2025 | msn.com

Ocugen CEO to Present at Prestigious Cell & Gene Meeting on the Mediterranean

April 10, 2025 | msn.com

Ocugen management to meet with Maxim

April 9, 2025 | markets.businessinsider.com

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

April 8, 2025 | globenewswire.com

Stargardt Disease Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Acucela, Astellas Pharma, Alkeus Pharma

April 7, 2025 | theglobeandmail.com

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

March 21, 2025 | ophthalmologytimes.com

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

March 19, 2025 | clinicaltrialsarena.com

Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results

March 19, 2025 | msn.com

Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial

March 18, 2025 | markets.businessinsider.com

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

March 18, 2025 | globenewswire.com

Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf

March 6, 2025 | financialpost.com

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

March 6, 2025 | seekingalpha.com

Ocugen reports Q4 EPS (5c), consensus (5c)

March 6, 2025 | markets.businessinsider.com

Ocugen (OCGN) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

Ocugen Reports Progress in Gene Therapy Trials

March 5, 2025 | tipranks.com

Ocugen, Inc. Reports Progress on Clinical Trials and FDA Alignment for OCU410ST in Stargardt Disease, Highlights Positive Long-Term Data for OCU400

March 5, 2025 | quiverquant.com

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

March 5, 2025 | globenewswire.com

Noble Financial Sticks to Its Buy Rating for Ocugen (OCGN)

March 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
By Jeffrey Neal Johnson | April 6, 2025
View Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?

FSDDF, ESPR, OCGN, and BTMD Company Descriptions

biote NASDAQ:BTMD

$3.47 +0.04 (+1.17%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$3.49 +0.02 (+0.58%)

As of 04/28/2025 06:19 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Esperion Therapeutics NASDAQ:ESPR

$0.91 -0.01 (-1.38%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$0.91 +0.01 (+0.63%)

As of 05:38 AM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

FSD Pharma OTCMKTS:FSDDF

$7.08 +0.17 (+2.46%)

As of 04/25/2025

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.

Ocugen NASDAQ:OCGN

$0.71 -0.01 (-1.28%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$0.71 0.00 (-0.28%)

As of 04:18 AM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time